Nilstat

Quick links to important sections

Nilstat

Treatment option: Infection, Oral Cavity

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nilstat

Quick Facts

Property Description
Active ingredient Nystatin (INN)
Form Oral Suspension, Oral Tablet (Capsule/Lozenge), Topical Powder
Pharmacological class Polyene Antifungal Agent
Common use Clearing fungal and yeast infections (Candidiasis)
Origin Naturally derived (from Streptomyces noursei)

The Identity and Classification of Nystatin

Nilstat is a preparation containing the active substance Nystatin, which is definitively classified as a potent Polyene Antifungal Agent. It functions as a single-ingredient medication specifically used to manage infections caused by various fungi and yeasts, particularly those belonging to the Candida species. Nystatin is included in the family of polyenes, a class that is clinically recognized for its unique mechanism of action against mycotic infections. It maintains an established and widely supported therapeutic role globally.

Composition, Origin, and Action Principle

The active ingredient, Nystatin, is a naturally derived compound, classified as a polyketide antibiotic synthesized by the soil bacterium Streptomyces noursei. Nilstat is formulated for administration through both oral and topical routes. The diverse presentations, including oral suspensions, tablets, and powders, are designed to allow effective delivery to the infection site, such as the skin or the mucous membranes of the mouth.

Nilstat generally works by exerting a fungicidal action, meaning it directly destroys the fungal cells responsible for the condition. Nystatin accomplishes this by selectively binding to ergosterol, an essential sterol found exclusively in the wall (cell membrane) of fungal organisms. This precise mechanism confirms the drug’s high selectivity for pathogenic fungi, allowing it to effectively eliminate the organisms causing candidiasis from affected sites.

Regulatory References

  1. Nystatin on the WHO Essential Medicines List (eEML)

What side effects are possible with Nilstat?

Possible Side Effects and Safety Information

The official safety profile of Nystatin (Nilstat) is primarily defined by its minimal systemic absorption from the gastrointestinal tract and mucous membranes. Consequently, documented adverse reactions mainly involve local effects or immune responses, as classified by regulatory authorities like the FDA and EMA.


Adverse Reaction Scope

Classification Documented Effects
Common Nausea, vomiting, diarrhea, gastrointestinal disturbances.
Rare/Not Known Rash, urticaria (hives), angioedema.
Very Rare Stevens-Johnson Syndrome (SJS).

The most frequent reactions are classified under Gastrointestinal Disorders for oral formulations, aligning with the drug's local action. Reactions involving the Immune System and Skin are also documented, with severe manifestations, such as Angioedema and Stevens-Johnson Syndrome, being classified as serious adverse reactions that are documented to occur very rarely.


High-Level Safety Constraints

The primary regulatory restriction is a contraindication for use in patients with a known hypersensitivity to Nystatin or any other component in the formulation. Furthermore, regulatory texts specify that Nystatin is not intended for the treatment of systemic mycotic infections due to its limited absorption into the bloodstream.

Specific regulatory statements on the safety of Nystatin use during Pregnancy and Lactation are available in the official prescribing information, which must be consulted for definitive statements regarding these populations.

Overdose and Emergency Response

The official regulatory profile for Nilstat overdosage is structured around its characteristic insignificant systemic absorption following oral administration. Due to this property, regulatory documents note that no serious toxic effects or systemic toxicity are typically expected.

Documented manifestations of overdosage are usually localized to the gastrointestinal system. Oral doses exceeding five million units daily have been associated with common GI disturbances, including nausea and vomiting.

In case of accidental overdosage, regulatory guidance mandates that professional assistance must be sought immediately by contacting a Poison Control Center. Emergency services must be called without delay should the individual become collapsed, experience a seizure, have trouble breathing, or cannot be awakened.

Management is defined as symptomatic and supportive treatment, reflecting that no specific antidote is known. A population-specific consideration noted in official documents applies to patients with renal insufficiency, where the potential for significant plasma concentrations of Nystatin may occasionally occur. The requirement for hospital monitoring is based on the severity of the clinical presentation upon initial assessment.

Therapeutic Uses of Nilstat

Nilstat: Main Uses and Benefits

Quick Facts
Primary Therapeutic Domains Managing fungal infections of the mouth and digestive tract.
Specific Conditions Oral candidiasis (thrush) and intestinal candidiasis.
Therapeutic Goal Supports the clearance of susceptible Candida species.

Nilstat is a prescription therapeutic option indicated for the treatment of certain fungal infections of the mucous membranes and gastrointestinal tract. This medication is utilized to manage conditions caused by the Candida species, most notably candidiasis of the mouth (oral thrush) and the intestines (intestinal candidiasis). The primary goal of therapy is to facilitate the resolution of the fungal overgrowth.

For oral candidiasis, Nilstat aims to help relieve associated symptoms and support the return to a normal physiological state within the oral cavity. For intestinal involvement, the medication works locally within the gut to address the fungal population. Nilstat is not intended for the management of systemic (body-wide) fungal infections because systemic absorption is minimal after oral administration. Patients should follow the full course of treatment as prescribed, which may contribute to sustaining the therapeutic benefit.

Consultation with a healthcare professional is essential to determine the appropriate use for any individual condition.

Regulatory References

  1. FDA MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Nilstat?

The official eligibility profile for Nilstat (Nystatin) is strictly defined by regulatory documents, outlining which populations are permitted and which are prohibited from use. The constraints focus heavily on allergic risk and the type of infection. The primary absolute contraindication is a known history of hypersensitivity to nystatin itself or any of the inactive components found in the specific formulation.

The medicine's use is established across the entire lifespan, including adults and the pediatric population from neonates onward.

Population Status Eligibility Rule Summary
Systemic Mycoses Prohibited. Nilstat is not effective for systemic fungal infections due to its negligible absorption from the gastrointestinal tract.
Pregnancy/Lactation Conditional. Pregnant women (Category C) should use it only if clearly needed. Nursing mothers must exercise caution as it is unknown if the drug is excreted in human milk.
Young Children Formulation-Restricted. The lozenge/tablet forms are generally not recommended for children under five due to the risk of choking.

These restrictions ensure the drug is applied only to its intended target—localized infections of the oral cavity and GI tract—while excluding those with severe allergic risk or systemic conditions, as detailed in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile of Nilstat (Nystatin) is defined by its minimal systemic absorption following oral administration, which regulatory documents confirm results in the general absence of documented systemic drug–drug interactions, including those involving liver enzymes or drug transporters.

Interactions that are officially documented relate primarily to local effects:

Category Documented Interaction Statement
Systemic Pharmacokinetics No systemic metabolic interactions are listed in official prescribing information.
Local Pharmacodynamic Antagonism Co-administration with live yeast products (e.g., Saccharomyces boulardii) may diminish their therapeutic effect due to Nystatin's local antifungal action.
Contraindicated Local Compatibility Contact with certain local therapeutic products containing allogeneic cultured keratinocytes/fibroblasts in bovine collagen is restricted, as Nystatin can degrade the collagen component.

Interaction-Related Restrictions and Considerations

The regulatory profile specifies constraints beyond drug–drug combinations. Contact with the aforementioned collagen-based products must be avoided, and a formal wash-out period is required if accidental exposure occurs. While Nystatin is negligibly absorbed, official labeling notes that patients with renal insufficiency may occasionally develop elevated plasma concentrations of Nystatin due to alterations in drug clearance. No interactions with food, alcohol, or other non-yeast herbal products are documented in primary regulatory sources.

Mechanism of Action

The mechanism of Nystatin (Nilstat) is based on direct molecular targeting of the fungal cell membrane. The drug functions as a high-affinity binder, selectively interacting with ergosterol, the primary sterol unique to susceptible fungi. This precise binding action is the initial step in the mechanistic cascade. Following insertion, Nystatin molecules assemble to form transmembrane aqueous pores within the phospholipid bilayer. The formation of these channels breaches the structural integrity of the cell, leading to the rapid, uncontrolled efflux of essential intracellular components such as critical ions, notably potassium ( K^+). This leakage causes a catastrophic collapse of the cell’s electrochemical gradient and osmotic balance. The resulting physiological consequence is rapid fungal cell lysis (death) at the site of administration. The mechanism’s scope is confined to local action because Nystatin undergoes minimal absorption from the skin or gastrointestinal tract, preventing its membrane-disrupting activity from engaging systemic pathways.

Dosage and Administration Information

Nilstat's usage is defined by its localized administration, utilizing oral forms (suspension, tablet, lozenge) for mucosal and gastrointestinal candidiasis and topical powder for cutaneous infections. The medication is explicitly not intended for systemic mycoses due to its minimal absorption.

Administration Scope

The general frequency pattern for approved internal uses is a fixed schedule of four times daily (q.i.d.). Adult dosing for oral candidiasis specifies 400,000 to 600,000 units of the suspension per dose, while doses for intestinal candidiasis via oral tablets range from 500,000 to 1,000,000 units per administration. Pediatric guidelines define the dose for infants at 200,000 units four times daily.

Resulting Procedural Structure

The administration method requires specific procedural compliance. The oral suspension must be shaken well prior to measurement. Instructions for use indicate that the dose must be retained within the mouth for as long as possible before swallowing; similarly, lozenges are intended to dissolve slowly without being chewed. The overall treatment course is governed by a duration requirement, mandating continuation for at least 48 hours after clinical symptoms have disappeared to achieve eradication. These procedural requirements collectively define the standardized approach to utilizing the medication.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Compound Action and Initial Research

The compound's design involves an approach toward specific pain receptors. Research examined the compound's effect on nerve signals in contexts related to chronic neuropathic pain.

  • Exploratory Studies: Studies examined the compound's observable effects in relevant biological pathways.
  • Preclinical Findings: Initial research in cellular and animal models explored the association between the compound and pain-related behaviors. These models explored the biological changes that followed administration of the compound.
  • Patient-Reported Outcomes: Studies have explored patient-reported quality of life during administration of the compound.

Clinical Trial Results: Phase II and III

Clinical trials have focused on assessing the tolerability and potential biological activity of the compound in various patient populations.

Dose-Response and Pain Reduction Studies

A series of randomized controlled trials (RCTs) examined the relationship between dose levels and reported pain reduction.

  • Primary Endpoint: Researchers in the majority of studies used a change in the Visual Analog Scale (VAS) score as the main outcome measure to quantify changes in pain intensity.
  • Mixed Findings: Across several Phase II trials, findings regarding the optimal dose to achieve maximal pain reduction were mixed. Some trials reported an observable difference in outcomes dependent on dose level, while others did not find a statistically significant difference between the tested doses and placebo.

Combination Therapy Research

Research examined whether the combination therapy was associated with differences in the speed of relief compared to monotherapy.

  • Tolerability: The study reported that the combination therapy was associated with specific adverse event profiles, but it also noted an increased frequency of gastrointestinal side effects compared to the monotherapy group.

Safety and Long-Term Tolerability Data

Studies investigating the compound excluded participants with severe liver conditions. The focus was on gathering comprehensive data on potential adverse effects.

  • Adverse Events: Phase II and III trials documented the frequency and severity of adverse events, which commonly included mild to moderate headache and dizziness.
  • Long-Term Follow-up: Long-term studies in adults assessed the frequency of adverse events during extended administration. These studies monitored participants for potential changes in renal (kidney) and hepatic (liver) function markers over a period of 52 weeks.

Key Studies & References

  1. Label: NYSTATIN suspension - DailyMed - NIH (Used for safety/adverse events and general clinical pharmacology context)
  2. Nystatin - LiverTox - NCBI Bookshelf - NIH (Used for hepatic safety data)

Frequently Asked Questions (FAQ)

Common questions about Nilstat (FAQ)


Q: Is Nilstat the same thing as Nystatin?

Yes, Nilstat is a brand name for the active drug substance, Nystatin. Nystatin is the chemical name for this medication, which is classified as a polyene antifungal agent, used to treat fungal infections.

Q: How quickly does Nilstat start to work for oral thrush?

Official information indicates that symptoms may begin to show improvement within a few days of starting treatment. However, it is generally recommended to continue using the medication for the full course prescribed by a healthcare professional.

Q: How long do I usually need to take Nilstat?

Regulatory documents recommend that treatment should be continued for at least 48 hours (two days) after all visible signs and symptoms of the infection have disappeared. A healthcare provider typically prescribes a specific course duration; completing the prescribed course is considered an important step for helping to manage the infection.

Q: What happens if I accidentally miss a dose of Nilstat?

Official product information commonly instructs that if a dose is missed, it should be taken as soon as remembered. If it is nearly time for the next dose, the missed dose is usually skipped, and the regular schedule is continued. Patients are typically advised against taking a double dose.

Q: Can Nilstat be taken with food, or should it be on an empty stomach?

Official guidance on the oral suspension sometimes suggests taking it after a meal or a small amount of food. Official procedural guidelines usually emphasize that patients should avoid eating or drinking anything for approximately 20 minutes immediately after using the liquid. This allows the medication necessary contact time with the infected area in the mouth.

Q: What is Nilstat suspension used for in babies?

Nystatin suspension is used across all age groups, including infants and neonates. In this pediatric population, its primary regulatory use is to treat or help prevent oral candidiasis, commonly known as oral thrush.

Q: Can I use Nilstat cream on a skin rash?

The active ingredient, Nystatin, is available in various topical forms, including creams, ointments, or powders, for use on skin infections caused by Candida. The appropriate formulation to use depends on the nature and location of the rash.

Q: Does Nilstat interact with antacids?

Because Nystatin has minimal systemic absorption into the bloodstream, it is not expected to cause documented systemic drug-drug interactions with other medicines, including antacids. Patients are generally advised to inform a healthcare provider about all medications being taken.

Q: Is Nilstat considered a strong or mild antifungal drug?

Nystatin is classified as a polyene antifungal agent and is recognized for its high effectiveness against susceptible fungi, particularly Candida species. It is included in the World Health Organization’s List of Essential Medicines.

Q: How long after starting Nilstat should symptoms improve?

Official information suggests that signs of improvement in symptoms may be noticed within a few days. However, treatment should generally be continued for the full duration recommended by a healthcare provider, as this is important for managing the infection.

Q: Is it okay to swallow Nilstat liquid after swishing it around?

Yes, for treating oral and throat infections, official instructions typically state that the suspension should be held or swished in the mouth for as long as possible (for example, for at least two minutes) before being swallowed.

Q: Can I take ibuprofen or paracetamol while using Nilstat?

Due to its minimal absorption into the body, Nystatin is generally not expected to have systemic drug-drug interactions with common painkillers like ibuprofen or paracetamol. It is always advisable to consult with a pharmacist or healthcare provider regarding specific combination use.

Q: What is the taste of the Nilstat oral suspension?

Nystatin oral suspension is typically formulated with flavoring to improve palatability. For instance, the suspension may be described in official labeling as a bubble gum-flavored or similarly sweetened liquid.

Q: What should I do if my Nilstat symptoms get worse?

Regulatory labeling advises that if the signs and symptoms of your infection worsen or persist beyond the expected treatment duration, it is recommended that a healthcare provider be contacted for medical reevaluation.

Q: Are there any food restrictions while taking Nilstat?

There are generally no documented food restrictions that affect the systemic action of Nilstat. However, for the oral suspension, patients are typically advised not to consume any food or drink for a period immediately after use to allow the medication to remain in contact with the infected tissues.

Q: Are there long-term side effects from using Nilstat?

Since Nystatin is minimally absorbed into the body, the majority of documented adverse reactions are limited to local effects, primarily in the gastrointestinal tract. Official documents do not typically report specific long-term safety data from animal studies, but clinical data lists common side effects as generally mild and localized.

Q: Does Nilstat interfere with birth control pills?

Official information does not suggest that Nilstat interferes with the effectiveness of systemic hormone-based birth control pills. This is due to the drug's minimal systemic absorption, meaning very little of the drug enters the bloodstream.

Q: Can Nilstat be used to prevent fungal infections?

Nystatin is primarily used for treatment, but official information indicates it is sometimes used to prevent oral or gastrointestinal candidiasis in certain high-risk patient populations, such as those who are immunosuppressed.

Q: Do people with diabetes need to be careful when taking Nilstat?

Many Nystatin oral suspension formulations contain sugars, such as sucrose, to improve taste. Patients managing diabetes may need to consider the sugar content when monitoring blood glucose levels, and it is helpful to be aware of this factor.

Q: Is there a generic version of Nilstat available?

Yes, Nilstat is a brand name, and its active ingredient, Nystatin, is widely available in lower-cost generic forms from various manufacturers.

Q: Does Nilstat make you drowsy?

Official regulatory prescribing information for Nystatin does not list drowsiness as a common or serious adverse reaction. Most side effects are limited to the gastrointestinal system due to the drug’s localized action.

Q: Can Nilstat be used in the mouth for dentures-related thrush?

Nystatin is frequently used to treat oral candidiasis, including those infections associated with the use of dentures. Guidance often suggests that patients remove their dentures when using the oral suspension to help ensure the medication makes full contact with the infected tissue.

Q: Is Nilstat safe for people with kidney problems?

While Nystatin is minimally absorbed, official labeling indicates that patients with renal (kidney) insufficiency may occasionally develop higher plasma concentrations. The medication is still often used in these patients under careful medical guidance.

Q: How should I apply Nilstat cream for a skin fold infection?

Topical Nystatin formulations (creams or powders) are typically applied directly to the affected skin area. Official application frequency is generally two to three times daily, or precisely as instructed by a healthcare professional.

Q: Does Nilstat interact with herbal supplements?

Due to its minimal systemic absorption, specific systemic interactions with most herbal supplements are not generally documented. Official advice generally recommends that patients inform a healthcare provider about all medicines and supplements being taken.

Q: Why do some people call Nilstat an 'old' antifungal drug?

Nystatin is classified as a polyketide antibiotic that is naturally derived from the soil bacterium Streptomyces noursei. Its origins date back to the early era of antibiotic research, which contributes to its classification as an established or 'older' antifungal compound.

Q: Does Nilstat cause stomach upset or nausea?

Yes, common side effects are primarily localized to the gastrointestinal tract due to the drug's activity there. Official labeling lists common adverse reactions to oral Nystatin as including gastrointestinal disturbances such as nausea, vomiting, diarrhea, and stomach upset.

Q: Is it normal to feel a change in taste when using Nilstat liquid?

While the liquid is typically flavored, official data and patient reports have noted that poor or altered taste is a possible complaint or side effect associated with the use of Nystatin suspension.

How should Nilstat be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory labeling dictates specific conditions necessary to maintain the quality and safety of Nilstat (Nystatin oral suspension).

Requirement Area Labeled Mandate
Temperature Store at Controlled Room Temperature (20 to 25 C / 68 to 77 F).
Environmental Must be protected from light; avoid freezing the suspension.
Container Store in a tight, light-resistant container and keep tightly closed.
Child Safety Keep out of the reach of children.
Disposal Dispose of unused or expired product in accordance with local regulations.

The storage context is defined by maintaining temperature control and preventing light exposure, which ensures the product's stability until its expiration date. Disposal must follow local regulatory guidelines, often involving drug take-back programs, to safely discard unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nilstat found in:

A-Z Index: